What stocks does Mark Zuckerberg own?
Mark Zuckerberg's personal equity holdings are overwhelmingly concentrated in Meta Platforms, Inc. (ticker: META), the parent company of Facebook, Instagram, and WhatsApp, where he serves as co-founder, chairman, and chief executive officer. He owns hundreds of millions of Class A and Class B shares, giving him majority voting control. Beyond his massive insider stake in Meta, public disclosures do not show a diversified public equity portfolio managed via SEC 13F filings, though his family office and philanthropic initiatives occasionally hold diverse private assets.
Related FAQs
In clinical oncology, no single medication or therapeutic agent achieves a universal one hundred percent success rate across all types of cancer due to the extreme genetic and biological heterogeneity of tumors.
Bill Gates has not bought Costco as a company, but the Bill & Melinda Gates Foundation has held shares of Costco Wholesale in its investment portfolio for many years.
The Bill & Melinda Gates Foundation entered into an agreement to purchase equity shares in BioNTech on August 30, 2019, just months prior to the company's official public market initial offering and the onset of the global pandemic.
BioNTech SE (BNTX) is a clinical-stage biotechnology pioneer globally recognized for its revolutionary messenger RNA (mRNA) technology platform initially deployed for COVID-19 vaccines and now being aggressively expanded into oncology, infectious dis...
Medical science has successfully developed specific immunization tools that protect the human body against viral infections known to cause cellular mutations and subsequent malignancies over time.
No, Brookfield Infrastructure Partners L.P. (BIP) does not pay monthly dividends; it operates on a quarterly distribution schedule. These distributions are typically paid in March, June, September, and December.
Elon Musk rarely provides direct individual stock recommendations for retail investors, but his public commentary and business ventures frequently spotlight companies aligned with artificial intelligence, sustainable energy, electric vehicles, space ...
Pharmaceutical stocks are often considered a solid investment choice for portfolios seeking defensive stability, steady dividend yields, and long-term growth driven by aging global populations and continuous medical innovation.
Boyd Gaming Corporation, a premier nationwide multi-jurisdictional gaming and entertainment company operating dozens of casino resort properties across the United States, generates substantial annual financial revenues.
Equity analysts and healthcare portfolio managers evaluating high-growth biotechnology stocks frequently highlight innovative firms possessing robust clinical pipelines and strong commercial revenue trajectories.
Yes, the Bill & Melinda Gates Foundation made a direct investment in BioNTech by purchasing over 3 million ordinary shares in 2019.
Bill Gates has invested heavily in numerous cutting-edge biotechnology and genomic companies through his private investment vehicles and philanthropic foundation initiatives.
Through the diversified investment portfolio managed by the Bill & Melinda Gates Foundation Trust, as well as his personal holding vehicle Cascade Investment, Bill Gates holds significant equity stakes across multiple blue-chip corporate giants.
BioNTech SE faces an evolving future centered on leveraging its proprietary mRNA technology platform beyond infectious disease vaccines into breakthrough oncology treatments, personalized cancer immunotherapies, and advanced autoimmune disease therap...
Identifying the best biotechnology corporation for investment involves evaluating firms with strong clinical pipelines, FDA-approved commercial product revenues, robust balance sheets, and proven research leadership.
No, BioNTech SE does not pay a regular dividend. While the company issued a special, one-time dividend in 2022 following a period of high revenue, it has not established a recurring dividend program.
BioNTech outlined an aggressive strategic roadmap focusing on its oncology and infectious disease pipelines, announcing plans to initiate multiple new late-stage Phase 3 clinical trials and approach several major data readouts.